Vincristine and Adriamycin for Myeloma with Kidney Problems
Author Information
Author(s): R.G. Aitchison, I.A.G. Reilly, A.G. Morgan, N.H. Russell
Primary Institution: City Hospital, Nottingham, UK
Hypothesis
Is vincristine and adriamycin effective therapy for myeloma complicated by renal failure?
Conclusion
The study found that VAMP treatment can be safely used for myeloma complicated by renal failure and may improve outcomes.
Supporting Evidence
- All patients responded with a median reduction in paraprotein concentration of 75%.
- Three of the four patients dependent on dialysis at the time of treatment recovered sufficient renal function for dialysis to be withdrawn.
- The median survival for the whole group from diagnosis of myeloma is at least 25 months.
Takeaway
Doctors tested a new treatment for patients with a type of blood cancer and kidney problems, and it helped many of them feel better.
Methodology
The study evaluated the effectiveness and toxicity of VAMP/VAD treatment in eight patients with myeloma and renal failure.
Limitations
The number of patients involved is small, and follow-up is not yet long enough to assess the effect of maintenance chemotherapy.
Participant Demographics
Mean age 62, range 49-77; all had myeloma and renal failure.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website